Pregnancy and breastfeeding in hidradenitis suppurativa: A review of medication safety.
Erin K CollierJustine R SeivrightVivian Y ShiJennifer L HsiaoPublished in: Dermatologic therapy (2020)
Hidradenitis suppurativa (HS) is a chronic inflammatory disease that disproportionately affects women of childbearing age. Pregnancy influences HS severity for many women, thus diligent continued management throughout pregnancy and postpartum may be required. Herein, we provide an updated review of pregnancy and lactation safety data for HS medications, including topical antiseptic washes, topical and systemic antibiotics, biologic and nonbiologic immunomodulators, immunosuppressants, adjunct medical therapies, and pain medications, to help guide risk-benefit discussions between providers and HS patients.
Keyphrases
- pregnancy outcomes
- hidradenitis suppurativa
- preterm birth
- end stage renal disease
- polycystic ovary syndrome
- pregnant women
- chronic kidney disease
- healthcare
- rheumatoid arthritis
- ejection fraction
- oxidative stress
- chronic pain
- newly diagnosed
- type diabetes
- machine learning
- preterm infants
- insulin resistance
- pain management
- patient reported outcomes
- spinal cord injury
- human milk
- breast cancer risk
- artificial intelligence
- dairy cows